NCT05088057 is a Phase 2 clinical trial of Camrelizumab in Triple Negative Breast Cancer (TNBC), sponsored by Aiping Shi.

Who is sponsoring NCT05088057?

NCT05088057 is sponsored by Aiping Shi.

What drugs are being tested in NCT05088057?

Interventions in NCT05088057: Camrelizumab, Doxorubicin, Cyclophosphamide, Docetaxel.

What condition does NCT05088057 study?

NCT05088057 studies Triple Negative Breast Cancer (TNBC).

Is NCT05088057 still recruiting?

NCT05088057 is currently status unknown. Last updated 21 October 2021.

Last reviewed 2021-10-21 · How we verify

NCT05088057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Status unknown Phase 2 Last updated 21 October 2021

What this trial tests

Phase 2 trial testing Camrelizumab in Triple Negative Breast Cancer (TNBC) in 30 participants. Status unknown.

Timeline

20 September 2021

Primary endpoint
19 August 2024

1 November 2024

Quick facts

Lead sponsor	Aiping Shi
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 September 2021
Primary completion	19 August 2024
Estimated completion	1 November 2024
Sites	1 location across China

Drugs / interventions tested

Camrelizumab
Doxorubicin (doxorubicin) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Triple Negative Breast Cancer (TNBC) — all drugs for Triple Negative Breast Cancer (TNBC) →

Sponsor

Aiping Shi

Who can join

Adults 18 to 70, female only, with Triple Negative Breast Cancer (TNBC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab plus chemotherapy as neoadjuvant therapy and Camrelizumab as adjuvant therapy in participants who have triple negative breast cancer (TNBC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Research progress on immunotherapy in triple‑negative breast cancer (Review).
Zhang X, Ge X, Jiang T, Yang R, et al · · 2022 · cited 20× · PMID 35762339 · DOI 10.3892/ijo.2022.5385
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives.
Valenza C, Rizzo G, Passalacqua MI, Boldrini L, et al · · 2023 · cited 10× · PMID 36743524 · DOI 10.1177/17588359221146129
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review.
Xu RC, Zhang YW, Liu CC, Xu YY, et al · · 2025 · cited 3× · PMID 40443538 · DOI 10.1016/j.lanwpc.2024.101180

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Triple Negative Breast Cancer (TNBC)

Currently open trials in the same condition.

NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
NCT06606730 — Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05088057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aiping Shi
Last refreshed: 21 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05088057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing